ERBB2 and neoplasm: Several studies have demonstrated that the dual anti-HER2 regime of pyrotinib in combination with trastuzumab has shown significant anti-tumor activity in HER2 amplification, RAS wild-type mCRC patients who have become refractory to chemotherapy (Chang et al., 2022; Fu et al., 2023; Zhou et al., 2023).